+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Influenza Diagnostics Market by Product Type, Test Type, Sample Type, Technology, Mode of Testing / Setting, Disease Indication, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Influenza Diagnostics Market by Product Type, Test Type, Sample Type, Technology, Mode of Testing / Setting, Disease Indication, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Influenza Diagnostics Market by Product Type, Test Type, Sample Type, Technology, Mode of Testing / Setting, Disease Indication, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904860
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Influenza Diagnostics Market is projected to reach USD 2.09 Billion in 2026. It is expected to continue growing at a CAGR of 10.80%, reaching USD 3.89 Billion by 2032.

Influenza diagnostics are moving from episodic seasonal testing toward always-on respiratory infection intelligence. The clinical need is clear: the World Health Organization estimates that seasonal influenza causes about 1 billion infections annually, including 3 to 5 million severe cases and 290,000 to 650,000 respiratory deaths. These figures keep influenza testing central to emergency care, primary care, pediatrics, long-term care, occupational health, and public health surveillance.

The market is shaped by rapid influenza diagnostic tests, molecular assays such as RT-PCR and isothermal amplification, multiplex respiratory panels, point-of-care platforms, and laboratory information systems that connect test results to treatment decisions. Demand is strongest where clinicians need fast differentiation between influenza A, influenza B, SARS-CoV-2, RSV, and other respiratory pathogens to guide antiviral use, isolation, antibiotic stewardship, and hospital capacity planning.

Transformative Shifts in the Influenza Testing Landscape

The most important shift is the move from single-pathogen flu testing to syndromic respiratory diagnostics. During and after the COVID-19 pandemic, health systems accelerated adoption of multiplex assays that detect influenza, SARS-CoV-2, RSV, and other pathogens from one specimen. This has changed purchasing behavior, with laboratories and clinics increasingly prioritizing workflow efficiency, result turnaround time, and clinical actionability over test volume alone.

A second shift is the expansion of point-of-care molecular diagnostics. Traditional rapid antigen tests remain useful because they are inexpensive and can deliver results in minutes, but CDC guidance has long noted that rapid influenza diagnostic tests generally have lower sensitivity than molecular methods. As a result, near-patient molecular platforms are gaining importance in urgent care, emergency departments, pharmacies, and decentralized care settings where speed and accuracy both matter.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical layer across influenza diagnostics rather than a standalone product category. AI models support outbreak forecasting, test demand planning, laboratory workflow triage, and interpretation of large respiratory surveillance datasets. When linked with electronic health records, syndromic surveillance, weather patterns, mobility indicators, and historical positivity rates, AI can help health systems anticipate testing peaks and allocate reagents, staff, and instruments more efficiently.

AI also strengthens diagnostic operations by improving quality control, automating result review, and flagging unusual positivity patterns that may indicate localized outbreaks or specimen handling issues. The greatest near-term value is expected in decision support: combining test results with symptoms, exposure history, vaccination status, and local influenza activity to guide antiviral prescribing and infection control. Adoption will depend on validation, transparency, cybersecurity, and regulatory alignment.

Key Regional Insights: Global Demand Patterns

North America remains one of the most advanced influenza diagnostics regions due to high laboratory capacity, established CDC and Public Health Agency of Canada surveillance systems, broad use of molecular testing, and strong reimbursement pathways for clinically necessary respiratory testing. Europe benefits from coordinated influenza monitoring through national agencies and ECDC-linked surveillance, with demand supported by hospital networks, primary care sentinel systems, and a strong installed base of laboratory molecular platforms.

Asia-Pacific is a highly dynamic environment because of large population scale, recurring influenza burden, expanding hospital infrastructure, and government investment in infectious disease preparedness after COVID-19 and avian influenza concerns. China, Japan, India, South Korea, Australia, and ASEAN markets are expanding use of rapid and molecular respiratory testing at different speeds depending on reimbursement, access, and local manufacturing capacity.

Latin America, the Middle East, and Africa present rising opportunities as governments strengthen respiratory disease surveillance and decentralized diagnostics. Brazil and Mexico anchor Latin American demand, while GCC health systems invest in advanced hospital diagnostics and digital health. Across Africa, demand is supported by the need for scalable point-of-care testing, but adoption is constrained by affordability, procurement fragmentation, cold-chain logistics, and uneven access to molecular laboratories.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

In ASEAN, influenza diagnostics demand is tied to urban hospital expansion, travel-related surveillance, and the need to monitor overlapping respiratory outbreaks in tropical and subtropical climates where seasonality can be less predictable. The GCC is investing in high-acuity hospital systems, laboratory automation, and health security programs, making multiplex respiratory testing attractive for emergency departments, pilgrimage-related public health planning, and premium care networks.

The European Union supports a mature diagnostics environment through harmonized regulatory expectations, strong laboratory networks, and cross-border disease monitoring. BRICS countries represent high-volume demand because Brazil, Russia, India, China, and South Africa combine large patient populations with growing domestic diagnostics manufacturing and government-led infectious disease programs.

G7 markets are characterized by advanced reimbursement systems, early adoption of molecular and multiplex platforms, and strong clinical guideline influence. NATO countries, while not a healthcare bloc, increasingly view infectious disease readiness as part of resilience planning, supporting demand for diagnostics that can operate reliably across civilian, military, and emergency response settings.

Key Country Insights: Leading Influenza Diagnostics Markets

The United States leads in test menu breadth, point-of-care molecular adoption, and integration of influenza diagnostics with CDC surveillance and health system protocols. Canada emphasizes public health reporting and equitable access across provinces, while Mexico is expanding rapid and molecular respiratory testing through public and private providers. Brazil has strong national surveillance infrastructure and significant demand during Southern Hemisphere influenza seasons.

In Europe, the United Kingdom, Germany, France, Italy, and Spain show mature demand for laboratory-based molecular testing, hospital respiratory panels, and primary care surveillance. Germany and France benefit from strong laboratory networks; the United Kingdom has advanced public health analytics; Italy and Spain have significant hospital demand during seasonal surges. Russia maintains demand through public sector hospital systems and domestic diagnostics capacity.

In Asia-Pacific, China is a major volume market with expanding molecular testing infrastructure and government focus on respiratory pathogen monitoring. India combines high disease burden with growing private diagnostics chains and a need for affordable rapid testing. Japan and South Korea are advanced adopters of high-quality diagnostics, automation, and surveillance-linked testing. Australia benefits from strong seasonal monitoring, public health reporting, and established use of molecular respiratory assays.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platforms that combine speed, accuracy, and operational simplicity. Product portfolios need to cover both cost-sensitive rapid testing and higher-sensitivity molecular options, with clear positioning by care setting: home and pharmacy screening, urgent care triage, hospital admission testing, and reference laboratory confirmation.

Organizations should invest in multiplex respiratory panels that remain clinically focused and economically defensible. Overly broad panels may face reimbursement scrutiny, while targeted influenza, RSV, and SARS-CoV-2 combinations align closely with real-world clinical decisions. Partnerships with public health agencies, hospital networks, and digital surveillance platforms can strengthen access and demonstrate measurable value.

Manufacturers should also localize strategies by region. In mature markets, differentiation should center on turnaround time, connectivity, automation, and health-economic evidence. In emerging markets, affordability, rugged instruments, simplified procurement, training, and reliable reagent supply are decisive.

Research Methodology for Evidence-Based Analysis

This executive summary is based on secondary research and evidence synthesis from recognized public health and regulatory sources, including WHO influenza burden estimates, CDC diagnostic guidance, ECDC surveillance frameworks, national public health agencies, peer-reviewed literature, and publicly available regulatory information. The analysis emphasizes verified epidemiological patterns, clinical testing practices, technology adoption trends, and regional healthcare infrastructure factors.

The methodology combines qualitative assessment of industry drivers with comparative evaluation of diagnostic modalities, including rapid antigen tests, RT-PCR, isothermal molecular assays, multiplex panels, point-of-care platforms, and digital surveillance tools. Insights were reviewed for consistency with established clinical guidance and current respiratory disease preparedness priorities.

Conclusion: The Future of Influenza Diagnostics

Influenza diagnostics are becoming a strategic component of respiratory care, public health preparedness, and healthcare system efficiency. The field is no longer defined only by seasonal testing activity; it is increasingly shaped by molecular accuracy, multiplex capability, point-of-care deployment, data connectivity, and AI-enabled surveillance.

Organizations that align testing solutions with clinical workflows, reimbursement realities, and regional access needs will be well positioned for durable relevance. As influenza continues to overlap with RSV, COVID-19, and emerging respiratory threats, reliable diagnostics will remain essential for timely treatment, outbreak control, and informed health policy.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Influenza Diagnostics Market, by Product Type
7.1. Test Kits & Reagents
7.1.1. RIDT Kits
7.1.2. PCR Reagent Kits
7.1.3. Controls & Calibrators
7.2. Instruments / Analyzers
7.3. Consumables & Accessories
7.3.1. Swabs
7.3.2. Pipettes
7.3.3. Cartridges
7.3.4. Microplates
8. Influenza Diagnostics Market, by Test Type
8.1. Rapid Antigen Tests
8.1.1. Lateral Flow Tests
8.1.2. Immunoassay Tests
8.2. Molecular Tests
8.2.1. RT-PCR Singleplex Tests
8.2.2. RT-PCR Multiplex Respiratory Tests
8.2.3. Isothermal Amplification Tests
8.3. Serology Tests
8.3.1. IgM Antibody Tests
8.3.2. Total Antibody Tests
8.3.3. IgG Antibody Tests
8.4. Reference & Advanced Characterization Tests
8.4.1. Viral Culture-Based Tests
8.4.2. Sequencing-Based Strain Characterization Tests
8.4.3. Subtyping And Surveillance Assays
9. Influenza Diagnostics Market, by Sample Type
9.1. Nasopharyngeal Swabs
9.2. Bronchoalveolar Lavage (BAL)
9.3. Oropharyngeal Swabs
9.4. Blood/serum Swabs
9.5. Nasal Swabs
10. Influenza Diagnostics Market, by Technology
10.1. Immunoassay-Based
10.1.1. Enzyme Immunoassay
10.1.2. Chemiluminescent Immunoassay
10.2. Polymerase Chain Reaction
10.3. Isothermal Amplification Technologies
11. Influenza Diagnostics Market, by Mode of Testing / Setting
11.1. Point-of-Care Testing (POCT)
11.2. Laboratory Testing
11.3. Home-Based Testing
12. Influenza Diagnostics Market, by Disease Indication
12.1. Influenza A
12.2. Influenza B
12.3. Seasonal Influenza infections
12.4. Pandemic / Novel Influenza
13. Influenza Diagnostics Market, by End User
13.1. Academic & Research Institutes
13.2. Clinics
13.3. Diagnostic Laboratories
13.4. Hospitals
14. Influenza Diagnostics Market, by Distribution Channel
14.1. Direct Sales
14.2. Distributors & Wholesalers
14.3. Online Medical Platforms
15. Asia-Pacific Influenza Diagnostics Market
16. Europe Influenza Diagnostics Market
17. North America Influenza Diagnostics Market
18. Latin America Influenza Diagnostics Market
19. Africa Influenza Diagnostics Market
20. Middle East Influenza Diagnostics Market
21. NATO Influenza Diagnostics Market
22. G7 Influenza Diagnostics Market
23. European Union Influenza Diagnostics Market
24. BRICS Influenza Diagnostics Market
25. ASEAN Influenza Diagnostics Market
26. GCC Influenza Diagnostics Market
27. United States Influenza Diagnostics Market
28. China Influenza Diagnostics Market
29. Germany Influenza Diagnostics Market
30. Japan Influenza Diagnostics Market
31. India Influenza Diagnostics Market
32. United Kingdom Influenza Diagnostics Market
33. Canada Influenza Diagnostics Market
34. France Influenza Diagnostics Market
35. Brazil Influenza Diagnostics Market
36. Mexico Influenza Diagnostics Market
37. Italy Influenza Diagnostics Market
38. Australia Influenza Diagnostics Market
39. South Korea Influenza Diagnostics Market
40. Russia Influenza Diagnostics Market
41. Spain Influenza Diagnostics Market
42. Competitive Landscape
42.1. Market Concentration Analysis, 2025
42.1.1. Concentration Ratio (CR)
42.1.2. Herfindahl Hirschman Index (HHI)
42.2. Recent Developments & Impact Analysis, 2025
42.3. Product Portfolio Analysis, 2025
42.4. Benchmarking Analysis, 2025
43. Company Profiles
43.1. Abbott Laboratories
43.2. F. Hoffmann-La Roche Ltd.
43.3. QuidelOrtho Corporation
43.4. Thermo Fisher Scientific
43.5. Siemens Healthineers AG
43.6. Qiagen N.V.
43.7. Becton, Dickinson and Company
43.8. Seegene, Inc.
43.9. DiaSorin S.p.A.
43.10. Hologic, Inc.
43.11. Agilent Technologies, Inc.
43.12. Bio-Rad Laboratories, Inc.
43.13. Guangzhou Wondfo Biotech Co., Ltd.
43.14. Cocrystal Pharma, Inc.
43.15. Visby Medical, Inc.
43.16. Access Bio, Inc.
43.17. ACON Laboratories, Inc.
43.18. Bioneer Corporation
43.19. CSL Limited
43.20. GenBody Inc.
43.21. Hangzhou AllTest Biotech Co., Ltd.
43.22. Jiangsu Bioperfectus Technologies Co., Ltd.
43.23. NATCO Pharma Limited
43.24. Novacyt S.A.
43.25. Novartis AG
43.26. R-Biopharm AG
43.27. Sansure Biotech Inc.
43.28. Shionogi & Co., Ltd.
43.29. Teva Pharmaceutical Industries Ltd.
43.30. Vircell, S.L.
43.31. Zydus Pharmaceuticals, Inc.
List of Figures
FIGURE 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2025 VS 2032 (%)
FIGURE 23. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
FIGURE 25. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 27. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 29. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 41. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 53. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 54. UNITED STATES INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. CHINA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. GERMANY INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. JAPAN INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. INDIA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. UNITED KINGDOM INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. CANADA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. FRANCE INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. BRAZIL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. MEXICO INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. ITALY INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. AUSTRALIA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SOUTH KOREA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 67. RUSSIA INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 68. SPAIN INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL INFLUENZA DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL INFLUENZA DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL TEST KITS & REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL TEST KITS & REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL TEST KITS & REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL RIDT KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL RIDT KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL RIDT KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PCR REAGENT KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PCR REAGENT KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PCR REAGENT KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INSTRUMENTS / ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL INSTRUMENTS / ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL INSTRUMENTS / ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL CONSUMABLES & ACCESSORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PIPETTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PIPETTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PIPETTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL CARTRIDGES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL CARTRIDGES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL CARTRIDGES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MICROPLATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MICROPLATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MICROPLATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL RAPID ANTIGEN TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL RAPID ANTIGEN TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL RAPID ANTIGEN TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL LATERAL FLOW TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL LATERAL FLOW TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL LATERAL FLOW TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNOASSAY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL IMMUNOASSAY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL IMMUNOASSAY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL RT-PCR SINGLEPLEX TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL RT-PCR SINGLEPLEX TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL RT-PCR SINGLEPLEX TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL RT-PCR MULTIPLEX RESPIRATORY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL RT-PCR MULTIPLEX RESPIRATORY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL RT-PCR MULTIPLEX RESPIRATORY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ISOTHERMAL AMPLIFICATION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SEROLOGY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SEROLOGY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SEROLOGY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL IGM ANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL IGM ANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL IGM ANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL TOTAL ANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL TOTAL ANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL TOTAL ANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL IGG ANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL IGG ANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL IGG ANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL REFERENCE & ADVANCED CHARACTERIZATION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL REFERENCE & ADVANCED CHARACTERIZATION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL REFERENCE & ADVANCED CHARACTERIZATION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL VIRAL CULTURE-BASED TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL VIRAL CULTURE-BASED TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL VIRAL CULTURE-BASED TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SEQUENCING-BASED STRAIN CHARACTERIZATION TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SEQUENCING-BASED STRAIN CHARACTERIZATION TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SEQUENCING-BASED STRAIN CHARACTERIZATION TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SUBTYPING AND SURVEILLANCE ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SUBTYPING AND SURVEILLANCE ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL SUBTYPING AND SURVEILLANCE ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NASOPHARYNGEAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL BRONCHOALVEOLAR LAVAGE (BAL) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL OROPHARYNGEAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL OROPHARYNGEAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL OROPHARYNGEAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL BLOOD/SERUM SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL BLOOD/SERUM SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL BLOOD/SERUM SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NASAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NASAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NASAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL IMMUNOASSAY-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL IMMUNOASSAY-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL IMMUNOASSAY-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ENZYME IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ENZYME IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ENZYME IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CHEMILUMINESCENT IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ISOTHERMAL AMPLIFICATION TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL ISOTHERMAL AMPLIFICATION TECHNOLOGIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL ISOTHERMAL AMPLIFICATION TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL POINT-OF-CARE TESTING (POCT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL POINT-OF-CARE TESTING (POCT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL POINT-OF-CARE TESTING (POCT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL HOME-BASED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL HOME-BASED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL HOME-BASED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL INFLUENZA A MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL INFLUENZA A MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL INFLUENZA A MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL INFLUENZA B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL INFLUENZA B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL INFLUENZA B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL SEASONAL INFLUENZA INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL SEASONAL INFLUENZA INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL SEASONAL INFLUENZA INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL PANDEMIC / NOVEL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL PANDEMIC / NOVEL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL PANDEMIC / NOVEL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 152. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. GLOBAL DIRECT SALES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 155. GLOBAL DIRECT SALES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 156. GLOBAL DIRECT SALES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. GLOBAL DISTRIBUTORS & WHOLESALERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL DISTRIBUTORS & WHOLESALERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL DISTRIBUTORS & WHOLESALERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. GLOBAL ONLINE MEDICAL PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL ONLINE MEDICAL PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. GLOBAL ONLINE MEDICAL PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 179. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 180. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 181. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 182. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 183. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 184. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 185. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 186. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 187. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 188. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 189. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 191. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 192. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 193. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 194. EUROPE INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 195. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 196. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 197. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 198. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 199. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 200. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 201. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 202. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 203. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 204. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 205. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 206. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 207. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 208. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 209. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. NORTH AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 211. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 212. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 213. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 214. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 215. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 216. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 217. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 218. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 219. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 220. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 221. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 222. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 223. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 224. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 225. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 226. LATIN AMERICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 227. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 228. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 229. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 230. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 231. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 232. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 233. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 234. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 235. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 236. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 237. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 238. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 239. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 240. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 241. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. AFRICA INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 244. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 245. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 246. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 247. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 248. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 249. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 250. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 251. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 252. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 253. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 254. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 255. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 256. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 257. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 258. MIDDLE EAST INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 259. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 260. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 261. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 262. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 263. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 264. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 265. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 266. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 267. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 268. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 269. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 270. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 271. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 272. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 273. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 274. NATO INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 275. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 276. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 277. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 278. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 279. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 280. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 281. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 282. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 283. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 284. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 285. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 286. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 287. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 288. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 289. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 290. G7 INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 307. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 308. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 309. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 310. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 311. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 312. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 313. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 314. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 315. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 316. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 317. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 318. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 319. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 320. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 321. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 322. BRICS INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 323. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 324. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 325. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 326. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 327. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 328. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 329. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 330. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 331. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE & ADVANCED CHARACTERIZATION TESTS, 2018-2032 (USD MILLION)
TABLE 332. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 333. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 334. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY-BASED, 2018-2032 (USD MILLION)
TABLE 335. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY MODE OF TESTING / SETTING, 2018-2032 (USD MILLION)
TABLE 336. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
TABLE 337. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 338. ASEAN INFLUENZA DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 339. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 340. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 341. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST KITS & REAGENTS, 2018-2032 (USD MILLION)
TABLE 342. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY CONSUMABLES & ACCESSORIES, 2018-2032 (USD MILLION)
TABLE 343. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 344. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY RAPID ANTIGEN TESTS, 2018-2032 (USD MILLION)
TABLE 345. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
TABLE 346. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY SEROLOGY TESTS, 2018-2032 (USD MILLION)
TABLE 347. GCC INFLUENZA DIAGNOSTICS MARKET SIZE, BY REFERENCE &

Companies Mentioned

The companies featured in this Influenza Diagnostics market report include:
  • Abbott Laboratories
  • F. Hoffmann‑La Roche Ltd.
  • QuidelOrtho Corporation
  • Thermo Fisher Scientific
  • Siemens Healthineers AG
  • Qiagen N.V.
  • Becton, Dickinson and Company
  • Seegene, Inc.
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Cocrystal Pharma, Inc.
  • Visby Medical, Inc.
  • Access Bio, Inc.
  • ACON Laboratories, Inc.
  • Bioneer Corporation
  • CSL Limited
  • GenBody Inc.
  • Hangzhou AllTest Biotech Co., Ltd.
  • Jiangsu Bioperfectus Technologies Co., Ltd.
  • NATCO Pharma Limited
  • Novacyt S.A.
  • Novartis AG
  • R‑Biopharm AG
  • Sansure Biotech Inc.
  • Shionogi & Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vircell, S.L.
  • Zydus Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages186
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.09 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.89 Billion
Compound Annual Growth Rate10.8%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Influenza Diagnostics Market Report by Product, Test Type, Type of Flu, End User, and Region ?2026-2034? - Product Image

Influenza Diagnostics Market Report by Product, Test Type, Type of Flu, End User, and Region ?2026-2034?

  • Report
  • 148 Pages
  • Global
From
Point-of-Care Influenza Diagnostics Market Forecast to 2033 - Product Image

Point-of-Care Influenza Diagnostics Market Forecast to 2033

  • Report
  • 150 Pages
  • Global
From
Influenza Diagnostic Market Report 2026 - Product Image

Influenza Diagnostic Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Influenza Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Influenza Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Influenza Diagnostic Tests Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type, End User, Product, Mode of Testing - Product Image

Influenza Diagnostic Tests Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type, End User, Product, Mode of Testing

  • Report
  • 160 Pages
  • Global
From

About the Influenza Test Market

The Influenza Test market is a subset of the larger Infectious Disease Testing market. It is used to detect the presence of the influenza virus in a patient's sample. Tests can be conducted using a variety of methods, including rapid antigen tests, molecular tests, and serological tests. Rapid antigen tests are the most commonly used, as they provide results in a short amount of time. Molecular tests are more accurate, but take longer to process. Serological tests are used to detect antibodies to the virus, and are used to diagnose past infections. The Influenza Test market is highly competitive, with many companies offering a variety of tests. Some of the major players in the market include Abbott, Becton Dickinson, Roche, Quidel, and Cepheid. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.